BRPI0507248A - compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares - Google Patents

compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares

Info

Publication number
BRPI0507248A
BRPI0507248A BRPI0507248-4A BRPI0507248A BRPI0507248A BR PI0507248 A BRPI0507248 A BR PI0507248A BR PI0507248 A BRPI0507248 A BR PI0507248A BR PI0507248 A BRPI0507248 A BR PI0507248A
Authority
BR
Brazil
Prior art keywords
hydrazine
compounds
treatment
pharmaceutical compositions
cardiovascular disease
Prior art date
Application number
BRPI0507248-4A
Other languages
English (en)
Inventor
Gerard Marguerie
Eric Malaud
Original Assignee
Clinigenetics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinigenetics filed Critical Clinigenetics
Publication of BRPI0507248A publication Critical patent/BRPI0507248A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTOS DO TIPO HIDRAZINA E SEU USO EM COMPOSIçõES FARMACêUTICAS PARA O TRATAMENTO DE DOENçAS CARIOVASCULARES. A presente invenção se refere aos compostos de fórmula gera (I), onde R1 e R2, idênticos ou diferentes, são selecionados a partir de um átomo de hidrogênio, um radical alquila inferior linear ou ramificado de 1 a 6 átomos de carbono, um radical fluoroalquila de 1 a 6 átomos de carbono e de 3 a 7 átomos de flúor, -A representa um grupo aromático com um ou vários ciclos que compreendem opcionalmente um ou vários heteroátomos, -B representa um grupo fenila opcionalmente substituído ou um grupo piridina opcionalmente substituído.
BRPI0507248-4A 2004-01-30 2005-01-31 compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares BRPI0507248A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400913A FR2865732B1 (fr) 2004-01-30 2004-01-30 Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires
PCT/FR2005/000199 WO2005082882A1 (fr) 2004-01-30 2005-01-31 Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
BRPI0507248A true BRPI0507248A (pt) 2007-06-26

Family

ID=34746342

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507248-4A BRPI0507248A (pt) 2004-01-30 2005-01-31 compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares

Country Status (15)

Country Link
US (1) US20070161697A1 (pt)
EP (2) EP1709027B1 (pt)
JP (1) JP5047629B2 (pt)
CN (1) CN100588655C (pt)
AT (1) ATE444961T1 (pt)
AU (1) AU2005217174B2 (pt)
BR (1) BRPI0507248A (pt)
CA (1) CA2554439A1 (pt)
DE (1) DE602005017007D1 (pt)
DK (1) DK2113502T3 (pt)
ES (2) ES2398479T3 (pt)
FR (1) FR2865732B1 (pt)
PT (2) PT1709027E (pt)
WO (1) WO2005082882A1 (pt)
ZA (1) ZA200606909B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132583A1 (en) * 2005-06-07 2006-12-14 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
EP2338879A1 (en) 2009-12-15 2011-06-29 Arteria New phenylhydrazone derivatives and their use as pharmaceuticals
WO2012027548A1 (en) * 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
CN103044284A (zh) * 2011-10-13 2013-04-17 南京大学 香草酸酰腙类衍生物及其制备和用途
WO2014028946A2 (en) * 2012-08-17 2014-02-20 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN103613514B (zh) * 2013-10-30 2015-05-13 西北师范大学 荧光比色识别氰根离子的有机双金属凝胶及其制备和应用
CN104829597B (zh) * 2015-05-25 2018-07-17 厦门大学 1h-吲哚-2-碳酰肼衍生物及其制备方法和用途
CN104860866B (zh) * 2015-05-25 2018-07-17 厦门大学 5-(取代碳酰氨基)-1h-吲哚-2-碳酰肼衍生物及其制备方法和应用
CN105348170B (zh) * 2015-11-06 2019-02-05 厦门大学 1-(2-(碳酰肼取代基团)-1h-吲哚-5-基)-3-取代脲衍生物及制备方法
EP3515427A4 (en) 2016-09-26 2020-10-14 Qingdao Primedicine Pharmaceutical Co., Ltd ALLOSTERIC N-METHYL-D-ASPARATE RECEPTOR MODULATORS AND METHOD OF USE
PL233208B1 (pl) * 2018-09-17 2019-09-30 Politechnika Wroclawska Iminowe pochodne aldehydów salicylowych i hydrazydu kwasu 4-hydroksybenzoesowego oraz sposób ich wytwarzania
WO2023060161A1 (en) * 2021-10-06 2023-04-13 The Research Foundation For The State University Of New York Anti-fungals compounds targeting the synthesis of fungal sphingolipids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB762187A (en) * 1952-10-09 1956-11-28 Bayer Ag Metal complexes of hydrazide-hydrazones and process for producing the same
JPS4819628B1 (pt) * 1969-01-07 1973-06-14
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3829492A (en) * 1972-02-04 1974-08-13 Rohm & Haas Fungicidal salicylaldehyde hydrazones and azines
US3963480A (en) * 1973-04-11 1976-06-15 Sterling Drug Inc. Herbicidal pyrrole-2-carboxamides
JPS62501709A (ja) * 1985-02-11 1987-07-09 ジ・アップジョン・カンパニ− 駆虫薬ピリジニル・アシルヒドラゾン、その使用方法および組成物
US5424333A (en) * 1985-10-21 1995-06-13 Rohm And Haas Company Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines
US6005113A (en) * 1996-05-15 1999-12-21 Molecular Probes, Inc. Long wavelength dyes for infrared tracing
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
JP2001233767A (ja) * 2000-02-25 2001-08-28 Shionogi & Co Ltd アポａｉ発現亢進剤
WO2002102301A2 (en) * 2000-12-07 2002-12-27 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002252976A1 (en) * 2001-01-22 2002-09-19 Arpida Ag Hydrazones and their therapeutic use
DE20108608U1 (de) * 2001-05-23 2001-08-09 Wella Ag, 64295 Darmstadt 2,5-Diamino-benzaldehyd-Derivate und diese Verbindungen enthaltende Färbemittel
EP1462105A1 (en) * 2003-03-28 2004-09-29 Procorde GmbH Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
WO2007142118A1 (ja) * 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. 多重リスク患者の心血管イベント発症予防用組成物

Also Published As

Publication number Publication date
ZA200606909B (en) 2007-12-27
JP2007519691A (ja) 2007-07-19
EP2113502A1 (fr) 2009-11-04
EP1709027A1 (fr) 2006-10-11
FR2865732A1 (fr) 2005-08-05
CN1950356A (zh) 2007-04-18
DE602005017007D1 (de) 2009-11-19
ES2398479T3 (es) 2013-03-19
DK2113502T3 (da) 2013-02-18
PT2113502E (pt) 2013-02-15
FR2865732B1 (fr) 2007-10-12
AU2005217174A1 (en) 2005-09-09
ATE444961T1 (de) 2009-10-15
JP5047629B2 (ja) 2012-10-10
EP1709027B1 (fr) 2009-10-07
ES2334574T3 (es) 2010-03-12
EP2113502B1 (fr) 2012-11-14
WO2005082882A1 (fr) 2005-09-09
PT1709027E (pt) 2010-01-13
US20070161697A1 (en) 2007-07-12
CN100588655C (zh) 2010-02-10
CA2554439A1 (fr) 2005-09-09
AU2005217174B2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0507248A (pt) compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
NO20065902L (no) 3-{4-(pyridin-3-yl)fenyl}-5-(1H-,1,2,3-triazol-1-ylmetyl)-1,3-oksazolidin-2-oner som antibakterielle midler
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
BR0009563A (pt) Inibidores de ap2 de bifenilas contendo heterocìclico e método
IT1314184B1 (it) Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
IT1311922B1 (it) Composti farmaceutici.
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
NO20074346L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
ATE489394T1 (de) Ä(4-oxo-4h-chromen-3-yl)-hydroxymethylü- oder ä(4-oxo-4h-chromen-3-yl)-methylü- phosphonsäurederivate
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
NO20081103L (no) 9-Aminoklarbonylsubstituerte derivater av glycylcykliner
DE69414396D1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
RU2365594C2 (ru) Применение циклических пептидов анабенопептинового типа для лечения состояния, при котором полезно ингибирование карбоксипептидазы u, новые анабенопептиновые производные и их промежуточные соединения
TH84863B (th) สารประกอบ, สารผสมที่มีสารเหล่านี้, การเตรียมสารเหล่านี้ และการใช้สารเหล่านี้
TH75305A (th) อนุพันธ์ 7-ฟีนิลอะมิโน-4-ควิโนโลน-3-คาร์บอกซิลิคแอซิด, กรรมวิธีสำหรับการเตรียมสารเหล่านี้ และการใช้สารเหล่านี้เป็นยา
TH85582A (th) อะมิโน คาร์บอกซิลิคที่ถูกแทนที่
TH82891B (th) 5-ซับสติติวเตด-2-ฟีนิลอะมิโน เบนซาไมด์ที่เป็นตัวยับยั้ง mek
TH51768B (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2291 DE 02/12/2014.